RATIONALE: Synthesis of ligands inactive or with low activity at α₁ GABA(A) receptors has become the key concept for development of novel, more tolerable benzodiazepine (BZ)-like drugs. WYS8, a remarkably (105 times) α₁-subtype selective partial positive modulator, may serve as a pharmacological tool for refining the role of α₁ GABA(A) receptors in mediation of BZs' effects. OBJECTIVES: Here, the effects of WYS8 on GABA-induced currents and on diazepam-induced potentiation of recombinant BZ-sensitive GABA(A) receptors were studied in more detail. In addition, the behavioral profile of WYS8 (0.2, 1, and 10 mg/kg i.p.), on its own and in combination with diazepam, was tested in the spontaneous locomotor activity, elevated plus maze, grip strength, rotarod, and pentylenetetrazole tests. RESULTS: WYS8, applied at an in vivo attainable concentration of 100 nM, reduced the stimulation of GABA currents by 1 μM diazepam by 57 % at α₁β₃γ₂, but not at α₂β₃γ₂, α₃β₃γ₂, or α₅β₃γ₂ GABA(A) receptors. The administration of WYS8 alone induced negligible behavioral consequences. When combined with diazepam, WYS8 caused a reduction in sedation, muscle relaxation, and anticonvulsant activity, as compared with this BZ alone, whereas ataxia was preserved, and the anxiolytic effect of 2 mg/kg diazepam was unmasked. CONCLUSIONS: Hence, a partial instead of full activation at α₁ GABA(A) receptors did not necessarily result in the attenuation of the effects assumed to be mediated by activation of these receptors, or in the full preservation of the effects mediated by activation of other GABA(A) receptors. Thus, the role of α₁ GABA(A) receptors appears more complex than that proposed by genetic studies.
RATIONALE: Synthesis of ligands inactive or with low activity at α₁ GABA(A) receptors has become the key concept for development of novel, more tolerable benzodiazepine (BZ)-like drugs. WYS8, a remarkably (105 times) α₁-subtype selective partial positive modulator, may serve as a pharmacological tool for refining the role of α₁ GABA(A) receptors in mediation of BZs' effects. OBJECTIVES: Here, the effects of WYS8 on GABA-induced currents and on diazepam-induced potentiation of recombinant BZ-sensitive GABA(A) receptors were studied in more detail. In addition, the behavioral profile of WYS8 (0.2, 1, and 10 mg/kg i.p.), on its own and in combination with diazepam, was tested in the spontaneous locomotor activity, elevated plus maze, grip strength, rotarod, and pentylenetetrazole tests. RESULTS:WYS8, applied at an in vivo attainable concentration of 100 nM, reduced the stimulation of GABA currents by 1 μM diazepam by 57 % at α₁β₃γ₂, but not at α₂β₃γ₂, α₃β₃γ₂, or α₅β₃γ₂ GABA(A) receptors. The administration of WYS8 alone induced negligible behavioral consequences. When combined with diazepam, WYS8 caused a reduction in sedation, muscle relaxation, and anticonvulsant activity, as compared with this BZ alone, whereas ataxia was preserved, and the anxiolytic effect of 2 mg/kg diazepam was unmasked. CONCLUSIONS: Hence, a partial instead of full activation at α₁ GABA(A) receptors did not necessarily result in the attenuation of the effects assumed to be mediated by activation of these receptors, or in the full preservation of the effects mediated by activation of other GABA(A) receptors. Thus, the role of α₁ GABA(A) receptors appears more complex than that proposed by genetic studies.
Authors: Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma Journal: Psychopharmacology (Berl) Date: 2002-09-04 Impact factor: 4.530
Authors: Joachim Ramerstorfer; Roman Furtmüller; Elisabeth Vogel; Sigismund Huck; Werner Sieghart Journal: Eur J Pharmacol Date: 2010-03-19 Impact factor: 4.432
Authors: A Lippa; P Czobor; J Stark; B Beer; E Kostakis; M Gravielle; S Bandyopadhyay; S J Russek; T T Gibbs; D H Farb; P Skolnick Journal: Proc Natl Acad Sci U S A Date: 2005-05-03 Impact factor: 11.205
Authors: Marija Milić; Jovana Divljaković; Sundari Rallapalli; Michael L van Linn; Tamara Timić; James M Cook; Miroslav M Savić Journal: Behav Pharmacol Date: 2012-04 Impact factor: 2.293
Authors: Miroslav M Savić; Marija M Milinković; Sundari Rallapalli; Terry Clayton; Sroan Joksimović; Michael Van Linn; James M Cook Journal: Int J Neuropsychopharmacol Date: 2009-03-06 Impact factor: 5.176
Authors: Stephanie C Licata; Donna M Platt; James M Cook; Michael L Van Linn; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2008-11-25 Impact factor: 4.530